Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 800 results for "sandoz inc"

Sandoz Inc. - Strategic SWOT Analysis Review

GlobalData Sandoz Inc. - Strategic SWOT Analysis Review - provides a comprehensive insight into the company's history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the ..., 4 weeks ago

Allergan Sales, LLC v. Sandoz, Inc.

Case Name: , No. 12-cv-207-JRG, 15-cv-347-JRG, 2016 U.S. Dist. LEXIS 135088 (E.D. Tex. Sept. 30, 2016) (Gilstrap, J.) Drug Product and Patent(s)-in-Suit: Combigan® (brimonidine tartrate / timolol maleate ophthalmic solution); U.S. Patent No.
 JD Supra1 month ago

Amgen's Competition Against Its Top Products: A Comprehensive Look For 2017-2018

Amgen, Inc. ( AMGN ) is one of the largest biotechnology companies, with a market cap of $108.2 billion and a diverse portfolio. On October 27, Amgen reported third-quarter 2016 financial results. Amgen's Q3 revenues totaled $5.52 billion, which is ...
 Seeking Alpha1 week ago Amgen (AMGN) Q3 Earnings & Sales Top; Enbrel Hurts Stock  Yahoo! Canada1 month ago Amgen Is Melting Down  Seeking Alpha1 month ago

Nabriva Reports Third Quarter 2016 Financial Results

World News: 12:00 GMT Wednesday 16th November 2016 . [ Nabriva Therapeutics US, Inc via Globe Newswire via SPi World News ] VIENNA, Austria and KING OF PRUSSIA, Pa., Nov. 16, 2016 (GLOBE NEWSWIRE) (NASDAQ:NBRV) Nabriva Therapeutics AG, a clinical ...
 SPi World News3 weeks ago PFIZER REPORTS THIRD-QUARTER 2016 RESULTS  Business Wire1 month ago Momenta Pharmaceuticals Reports Third Quarter 2016 Financial Results  Citybizlist1 month ago Cambrex Corporation (NYSE:CBM) Files An 8-K  Pharmacy Choice1 month ago

FDA Accepts Coherus's aBLA for Neulasta® Biosimilar

In August, we reported that Coherus Biosciences, Inc. submitted an aBLA for CHS-1701, a pegfilgrastim (Neulasta®) biosimilar candidate. Last week, Coherus announced that FDA has accepted its aBLA. Under the BPCIA, Coherus has 20 days from FDA ...
 JD Supra1 month ago Coherus' Neulasta Biosimilar At FDA Altar, CytoDyn On Fast Track, VIVE Abuzz  RTTNews.com2 months ago Coherus Biosciences Could Be First-To-Market With A Neulasta Biosimilar  Yahoo! Finance2 months ago

global Biosimilars Market Report 2016-2025: Key Companies are Sandoz, Stada Arzneimittel, Amgen, Hospira, Actavis, Cipla, Wockhardt & Biocon

Dublin, Oct. 28, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the report to their offering. The market for biosimilars offers tremendous growth opportunities for the operating companies to record high revenue growth.
 Yahoo! Finance1 month ago Bromhexine Market Analysis and Growth Forecast by Applications, Types and Competitors to 2021  Before It's News5 days ago Global Protein Therapeutics Market worth USD 315.90 Billion by 2025 - Analysis, Technologies & Forecasts Report 2016-2025 - Vendors: - Research and Markets  Digital Journal2 weeks ago Global PDE Inhibitors Market Report 2016-2026: PDE4 has Surfaced to Address the Unmet Needs with Respiratory Diseases and Dermatological Disorders  BizWire Express2 weeks ago

Edited Transcript of PTX earnings conference call or presentation 11-Aug-16 8:30pm GMT

Q2 2016 Pernix Therapeutics Holdings Inc Earnings Call The Woodlands Oct 24, 2016 (Thomson StreetEvents) -- Edited Transcript of Pernix Therapeutics Holdings Inc earnings conference call or presentation Thursday, August 11, 2016 at 8:30:00pm GMT ...
 Yahoo! Finance1 month ago

Upsher-Smith Acquires 20 Generic Drug Products

MAPLE GROVE, Minn., Oct. 18, 2016 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith) today announced that it has acquired more than 20 US generic products from Sandoz, Inc. for an upfront payment in cash and additional payments ...
 Yahoo! Finance1 month ago Upsher-Smith Laboratories Acquires 20 Generic Drug Products  BioSpace1 month ago

A Compelling Risk/Reward Seen In Momenta Pharmaceuticals

Barclays sees a compelling risk/reward in Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) citing the Copaxone 40mg trial. The firm sees little risk in owning the stock pointing out successful IPR decisions, although no one could guarantee whether the ...
 Benzinga.com1 month ago

Aequus Pharmaceuticals Inc. (AQSZF: OTCQB) | Aequus Obtains Public Reimbursement for Vistitan in Two Additional Provinces: Alberta and Manitoba

) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that it has successfully ...
 OTC Markets5 days ago Aequus Obtains Public Reimbursement for Vistitan in Two Additional Provinces: Alberta and Manitoba  FirstWord Pharma5 days ago Aequus Provides Q3 2016 Financial Highlights With Substantial Increase in Quarter Over Quarter Revenues  Financial Buzz6 days ago AEQUUS PHARMACEUTICALS : Provides Q3 2016 Financial Highlights With Substantial Increase in Quarter Over Quarter Revenues  4 Traders6 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less